EFFECT OF SR-27417 ON THE BINDING OF [H-3] PAF TO RABBIT AND HUMAN PLATELETS AND HUMAN POLYMORPHONUCLEAR LEUKOCYTES

被引:0
|
作者
HERBERT, JM
LAPLACE, MC
CAILLEAU, C
MAFFRAND, JP
机构
来源
JOURNAL OF LIPID MEDIATORS | 1993年 / 7卷 / 01期
关键词
PLATELET-ACTIVATING FACTOR SR-27417; PLATELETS; LEUKOCYTES; BINDING;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
SR 27417, the first member of a newly developed PAF antogonist series, fully and competitively displaced [H-3]PAF from its high-affinity binding sites on washed rabbit and human platelets with K(i) values of 57 +/- 0.02 and 50 +/- 0.8 pM (n = 3), respectively. Studies carried out in parallel demonstrated that SR 27417 was 5-7-times more potent than C-16-PAF itself and more than 50-60-fold as active as the best synthetic PAF antagonist yet described. Additionally, SR 27417 selectively and competitively inhibited the specific binding of [H-3]WEB-2086, a selective PAF receptor antagonist to its high-affinity receptors on washed rabbit platelets (IC50 = 0.18 +/- 0.01 nM). On human polymorphonuclear leukocytes, [H-3]PAF bound to two classes of specific binding sites with high (K(D) = 0.31 +/- 0.05 nM; B(max) = 1.2 +/- 0.07 fmol/10(6) cells) and low affinity (K(D) = 11.1 +/- 1.5 nM; B(max) = 13.7 +/- 0.8 fmol/10(6) cells). On these cells, SR 27417 selectively inhibited the specific binding of [H-3]PAF to its high- and low-affinity receptors (lC50 values of 0.17 +/- 0.02 and 6.9 +/- 0.7 nM, respectively) and displayed the same inhibitory pattern as that already reported on platelets. In conclusion, SR 27417 can be considered as the most potent PAF receptor antagonist described to date.
引用
收藏
页码:57 / 78
页数:22
相关论文
共 50 条
  • [41] DIFFERENTIAL KINETICS OF BINDING OF (H-3)SQ29,548 AND (H-3)U46619 TO WASHED HUMAN PLATELETS
    PATRIGNANI, P
    VOLPI, D
    PATRONO, C
    CLINICAL RESEARCH, 1990, 38 (02): : A500 - A500
  • [42] SOLUBILIZATION AND ASSAY OF [H-3]IMIPRAMINE BINDING-SITES FROM HUMAN-PLATELETS
    DAVIS, A
    MORRIS, J
    TANG, SW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 86 (3-4) : 353 - 359
  • [43] COMPARISON OF FILTRATION AND EQUILIBRIUM DIALYSIS METHODS FOR [H-3]IMIPRAMINE BINDING TO HUMAN-PLATELETS
    LUI, N
    ALMON, RR
    JUSKO, WJ
    ANALYTICAL BIOCHEMISTRY, 1984, 139 (01) : 42 - 57
  • [44] KINETIC-PROPERTIES OF [H-3] 2-NITROIMIPRAMINE BINDING TO HUMAN-PLATELETS
    DAVIS, A
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 96 (1-2) : 105 - 110
  • [45] LONG-TERM VERAPAMIL TREATMENT INCREASES [H-3] IMIPRAMINE BINDING IN HUMAN PLATELETS
    COHEN, A
    WEIZMAN, A
    ELDAR, M
    REHAVI, M
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 181 (03) : 311 - 314
  • [46] UPTAKE, METABOLISM AND RELEASE OF H-3!-ADRENALINE BY HUMAN PLATELETS
    BORN, GVR
    SMITH, JB
    BRITISH JOURNAL OF PHARMACOLOGY, 1970, 39 (04) : 765 - &
  • [47] PAF BINDING-SITES - CHARACTERIZATION BY [H-3] 52770 RP, A PYRROLO[1,2-C]THIAZOLE DERIVATIVE, IN RABBIT PLATELETS
    ROBAUT, C
    DURAND, G
    JAMES, C
    LAVE, D
    SEDIVY, P
    FLOCH, A
    MONDOT, S
    PACOT, D
    CAVERO, I
    LEFUR, G
    BIOCHEMICAL PHARMACOLOGY, 1987, 36 (19) : 3221 - 3229
  • [48] CHARACTERISTICS OF IC3B BINDING TO HUMAN POLYMORPHONUCLEAR LEUKOCYTES (PMN)
    GORDON, DL
    HOSTETTER, MK
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1986, 16 (01): : 174 - 174
  • [49] 3H-PICOTAMIDE BINDING TO HUMAN PLATELETS
    MODESTI, PA
    COLELLA, A
    CECIONI, I
    ABBATE, R
    GENSINI, GF
    SERNERI, GGN
    THROMBOSIS RESEARCH, 1993, 70 : S113 - S113
  • [50] BINDING-SITES FOR [H-3] GLUTAMATE AND [H-3] ASPARTATE IN HUMAN CEREBELLUM
    CROSS, A
    SKAN, W
    SLATER, P
    JOURNAL OF NEUROCHEMISTRY, 1986, 47 (05) : 1463 - 1468